For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Riluzole - Motor neurone disease
PAD Profile : Riluzole - Motor neurone disease
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The Prescribing Clinical Network recommends the use of riluzole in line with NICE TA20, for the treatment of individuals with the amyotrophic lateral sclerosis (ALS) form of Motor Neurone Disease.
Riluzole should be only be initiated by a neurological specialist with expertise in the management of MND, but can be managed in primary care via a shared care agreement with general practitioners, and as such is considered as AMBER on the traffic light system.
PLEASE NOTE: In May 2017, the Prescribing Clinical Network recommended that the branded product Rilutek would be considered BLACK on the traffic light system.